OverviewSuggest Edit

Vectura's product development, formulation and drug delivery expertise is centred around developing inhaled products to address unmet needs in airways diseases. Vectura has established development collaborations, joint ventures and license agreements with several global pharmaceutical and biotechnology companies. Vectura is based in the UK, with headquarters in Chippenham, Wiltshire and operates in Cambridge (UK), Germany and a US operations office near Boston MA.
TypePublic
HQChippenham, GB
Websitevectura.com
Employee Ratings3.2

Latest Updates

Employees (est.) (Nov 2020)480
Job Openings12
Revenue (FY, 2018)£160.5 M(+9%)
Share Price (Nov 2020)£1.1
Cybersecurity ratingAMore

Key People/Management at Vectura Group

Olof Andersson

Olof Andersson

Non-Executive Director
Bruno Angelici

Bruno Angelici

Non-Executive Chairman
Thomas Werner

Thomas Werner

Senior Independent Non-Executive Director
Mark Bridgewater

Mark Bridgewater

Chief Commercial Officer
John Murphy

John Murphy

General Counsel and Company Secretary
Juliet Thompson

Juliet Thompson

Non-Executive Director
Show more

Vectura Group Office Locations

Vectura Group has offices in Chippenham, London, Milton, Saint-Quentin-Fallavier and in 2 other locations
Chippenham, GB (HQ)
1-6, Prospect West, Bumpers Way
London, GB
46-48 Grosvenor Gardens, Belgravia
Milton, GB
205 Cambridge Science Park Milton Rd
Saint-Quentin-Fallavier, FR
55 Rue du Montmurier
Gauting, DE
Robert-Koch-Allee 29
Muttenz, CH
Eptingerstrasse 61
Show all (6)

Vectura Group Financials and Metrics

Vectura Group Revenue

Embed Graph
View revenue for all periods
Vectura Group's revenue was reported to be £160.50 m in FY, 2018 which is a 8.4% increase from the previous period.
GBP

Revenue (FY, 2018)

160.5m

Revenue growth (FY, 2017 - FY, 2018), %

8.4%

Gross profit (FY, 2018)

98.9m

Gross profit margin (FY, 2018), %

61.6%

Net income (FY, 2018)

(88.2m)

EBITDA (FY, 2018)

163.4m

EBIT (FY, 2018)

30.6m

Market capitalization (13-Nov-2020)

625.7m

Closing stock price (13-Nov-2020)

1.1

Cash (31-Dec-2018)

108.2m
Vectura Group's current market capitalization is £625.7 m.
GBPFY, 2016FY, 2017FY, 2018

Revenue

72.0m148.0m160.5m

Revenue growth, %

24%106%8%

Cost of goods sold

3.3m57.2m61.6m

Gross profit

68.7m90.8m98.9m
GBPFY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

1.2m124.0k18.0k7.9m8.4m2.1m18.4m16.8m77.0m78.8m64.1m74.4m75.5m70.1m81.7m90.0m99.8m103.7m108.2m

Accounts Receivable

398.4k592.9k643.0k455.0k566.0k668.0k4.2m2.1m2.9m2.1m2.0m800.0k100.0k4.4m16.2m1.6m24.6m25.2m

Inventories

202.0k190.0k200.0k700.0k800.0k1.0m900.0k700.0k23.4m26.7m

Current Assets

9.7k1.3m952.5k787.4k8.8m9.5m2.8m19.2m21.5m86.0m85.0m78.4m83.8m85.9m80.1m96.4m118.8m122.7m161.2m170.2m
GBPFY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(96.1k)(512.9k)(998.1k)(1.1m)(2.7m)(5.5m)(8.1m)(7.7m)(6.5m)(6.8m)(19.2m)(10.2m)(8.8m)(4.4m)(5.9m)(2.3m)3.7m5.0m(85.7m)(88.2m)

Cash From Operating Activities

2.0m5.2m5.7m6.2m1.6m(6.5m)1.5m(3.8m)10.8m2.1m(2.8m)(700.0k)8.0m32.9m26.1m30.1m

Cash From Financing Activities

10.4m8.6m(854.0k)21.2m253.0k49.9m(2.3m)(5.7m)200.0k2.5m600.0k53.3m1.8m2.7m(3.2m)(14.8m)

Net Change in Cash

7.9m495.0k6.3m16.3m1.6m60.7m1.3m(9.9m)10.3m1.1m(5.4m)11.6m8.3m9.8m13.4m3.2m
GBPFY, 1998

Debt/Equity

-0.9 x

Debt/Assets

7.3 x

Financial Leverage

-0.1 x
Show all financial metrics

Vectura Group Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Vectura Group Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Vectura Group Online and Social Media Presence

Embed Graph

Vectura Group News and Updates

Asia Pacific Smart Inhalers Market is Expected to Grow at a CAGR of 27.2% in 2019-2027 with Top key players GlaxoSmithKline plc, Adherium Ltd., Vectura Group plc, Novartis AG, Cohero Health, 3M

The Asia Pacific smart inhalers market is expected to reach US$ 1,539.97 Mn in 2027 from US$ 186.63 Mn in 2018. The market is estimated to grow with a CAGR of 27.2% from 2019-2027. Posted via Industry Today. Follow us on Twitter @IndustryToday

Vectura Group plc - 2020 Interim Results

2020 Interim Results     

Vectura Group plc: 2019 Preliminary Results

2019 Preliminary Results     

Vectura Group Frequently Asked Questions

  • Who are Vectura Group key executives?

    Vectura Group's key executives are Olof Andersson, Bruno Angelici and Thomas Werner.

  • How many employees does Vectura Group have?

    Vectura Group has 112 employees.

  • What is Vectura Group revenue?

    Latest Vectura Group annual revenue is £160.5 m.

  • What is Vectura Group revenue per employee?

    Latest Vectura Group revenue per employee is £1.4 m.

  • Who are Vectura Group competitors?

    Competitors of Vectura Group include Genewiz, Univercells and Centrexion.

  • Where is Vectura Group headquarters?

    Vectura Group headquarters is located at 1-6, Prospect West, Bumpers Way, Chippenham.

  • Where are Vectura Group offices?

    Vectura Group has offices in Chippenham, London, Milton, Saint-Quentin-Fallavier and in 2 other locations.

  • How many offices does Vectura Group have?

    Vectura Group has 6 offices.